AAAAAA
Results: 1-25/40
Authors:
DILLMAN RO
NAYAK SK
BARTH NM
DELEON C
SCHWARTZBERG LS
SPITLER LE
CHURCH C
OCONNOR AA
BEUTEL LD
Citation: Ro. Dillman et al., CLINICAL-EXPERIENCE WITH AUTOLOGOUS TUMOR-CELL LINES FOR PATIENT-SPECIFIC VACCINE THERAPY IN METASTATIC MELANOMA, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 13(3), 1998, pp. 165-176
Authors:
SCHILTZ PM
NAYAK SK
DILLMAN RO
Citation: Pm. Schiltz et al., A NOVEL-APPROACH FOR GENERATING TUMOR-INFILTRATING LYMPHOCYTES (TIL) FROM RENAL-CELL CARCINOMA (RCC) IN THE PRESENCE OF AUTOLOGOUS DENDRITIC CELLS (DC) A TUMOR-ANTIGEN, Journal of leukocyte biology, 1998, pp. 9-9
Authors:
STARK JJ
DILLMAN RO
SCHULOF R
WIEMANN MC
BARTH NM
HONEYCUTT PJ
SOORI G
Citation: Jj. Stark et al., INTERFERON-ALPHA AND CHEMOHORMONAL THERAPY FOR PATIENTS WITH ADVANCEDMELANOMA - FINAL RESULTS OF A PHASE I-II STUDY OF THE CANCER-BIOTHERAPY-RESEARCH-GROUP AND THE MID-ATLANTIC-ONCOLOGY-PROGRAM, Cancer, 82(9), 1998, pp. 1677-1681
Authors:
DILLMAN RO
Citation: Ro. Dillman, MAGIC BULLETS AT LAST - FINALLY - APPROVAL OF A MONOCLONAL-ANTIBODY FOR THE TREATMENT OF CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 223-225
Authors:
DILLMAN RO
CRISPIN R
OLDHAM RK
Citation: Ro. Dillman et al., THE CANCER-BIOTHERAPY-RESEARCH-GROUP [CBRG], FORMERLY THE NATIONAL-BIOTHERAPY-STUDY-GROUP [NBSG] - A 10-YEAR PERSPECTIVE, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 229-242
Authors:
DILLMAN RO
CHURCH C
BARTH NM
OLDHAM RK
WIEMANN MC
Citation: Ro. Dillman et al., LONG-TERM SURVIVAL AFTER CONTINUOUS-INFUSION INTERLEUKIN-2, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 243-248
Authors:
DILLMAN RO
WIEMANN MC
VANDERMOLEN LA
BURY MJ
DEPRIEST C
CHURCH C
Citation: Ro. Dillman et al., HYBRID HIGH-DOSE BOLUS CONTINUOUS-INFUSION INTERLEUKIN-2 IN PATIENTS WITH METASTATIC MELANOMA - A PHASE-II TRIAL OF THE CANCER-BIOTHERAPY-RESEARCH-GROUP (FORMERLY THE NATIONAL-BIOTHERAPY-STUDY-GROUP), CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(4), 1997, pp. 249-255
Authors:
DILLMAN RO
HURWITZ SR
SCHILTZ PM
BARTH NM
BEUTEL LD
NAYAK SK
OCONNOR AA
Citation: Ro. Dillman et al., TUMOR-LOCALIZATION BY TUMOR-INFILTRATING LYMPHOCYTES LABELED WITH IN-111 IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA, MELANOMA, AND COLORECTAL-CANCER, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(2), 1997, pp. 65-71
Authors:
DILLMAN RO
WIEMANN MC
BURY MJ
CHURCH C
DEPRIEST C
Citation: Ro. Dillman et al., HYBRID HIGH-DOSE BOLUS CONTINUOUS INFUSION INTERLEUKIN-2 IN PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA - A PHASE-II TRIAL OF THE NATIONAL BIOTHERAPY STUDY-GROUP/, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 12(1), 1997, pp. 5-11
Authors:
SCHILTZ PM
BEUTEL LD
NAYAK SK
DILLMAN RO
Citation: Pm. Schiltz et al., CHARACTERIZATION OF TUMOR-INFILTRATING LYMPHOCYTES DERIVED FROM HUMANTUMORS FOR USE AS ADOPTIVE IMMUNOTHERAPY OF CANCER, Journal of immunotherapy with emphasis on tumor immunology, 20(5), 1997, pp. 377-386
Authors:
DILLMAN RO
BARTH NM
VANDERMOLEN LA
MAHDAVI K
NAYAK SK
Citation: Ro. Dillman et al., HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL RESCUE IN HEMATOLOGICMALIGNANCIES - SINGLE INSTITUTION EXPERIENCE, Blood, 90(10), 1997, pp. 4553-4553
Authors:
HARVEY SR
NAYAK SK
MARKUS G
OUHAMMOUCH M
HEMPERLY JJ
DILLMAN RO
DOYLE DJ
Citation: Sr. Harvey et al., CANCER-CELLS RELEASE A COVALENT COMPLEX CONTAINING DISULFIDE-LINKED DOMAINS FROM URINARY PLASMINOGEN-ACTIVATOR, NEURAL CELL-ADHESION MOLECULE, AND HAPTOGLOBIN ALPHA-CHAINS AND BETA-CHAINS, Archives of biochemistry and biophysics, 345(2), 1997, pp. 289-298
Authors:
DILLMAN RO
HERNDON J
SEAGREN SL
EATON WL
GREEN MR
Citation: Ro. Dillman et al., IMPROVED SURVIVAL IN STAGE-III NON-SMALL-CELL LUNG-CANCER - 7-YEAR FOLLOW-UP OF CANCER AND LEUKEMIA GROUP-B (CALGB)-8433 TRIAL, Journal of the National Cancer Institute, 88(17), 1996, pp. 1210-1215
Authors:
DILLMAN RO
Citation: Ro. Dillman, WHY EVENT-FREE SURVIVAL IS BETTER THAN TUMOR RESPONSE OR OTHER MEASURES OF SURVIVAL AS AN END-POINT IN CANCER TRIALS, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(2), 1996, pp. 99-104
Authors:
NAYAK SK
MCCALLISTER T
HAN LJ
GANGAVALLI R
BARBER J
DILLMAN RO
Citation: Sk. Nayak et al., TRANSDUCTION OF HUMAN RENAL-CARCINOMA CELLS WITH HUMAN GAMMA-INTERFERON GENE VIA RETROVIRAL VECTOR, Cancer gene therapy, 3(3), 1996, pp. 143-150
Authors:
DILLMAN RO
BARTH NM
NAYAK SK
DELEON C
OCONNOR A
MORRELLI L
Citation: Ro. Dillman et al., HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE IN BREAST-CANCER, Breast cancer research and treatment, 37(3), 1996, pp. 277-289
Authors:
DILLMAN RO
VANDERMOLEN LA
BARTH NM
BRANSFORD KJ
Citation: Ro. Dillman et al., MALIGNANT-MELANOMA AND PREGNANCY - 10 QUESTIONS, Western journal of medicine, 164(2), 1996, pp. 156-161
Authors:
DILLMAN RO
BARTH NM
VANDERMOLEN LA
MAHDAVI K
NAYAK SK
Citation: Ro. Dillman et al., SINGLE INSTITUTION EXPERIENCE WITH HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL RESCUE IN HEMATOLOGIC MALIGNANCIES - 1990-1996, Blood, 88(10), 1996, pp. 3856-3856
Authors:
DILLMAN RO
WIEMANN M
OLDHAM RK
SOORI G
BURY M
HAFER R
CHURCH C
DEPRIEST C
Citation: Ro. Dillman et al., INTERFERON ALPHA-2A AND EXTERNAL-BEAM RADIOTHERAPY IN THE INITIAL MANAGEMENT OF PATIENTS WITH GLIOMA - A PILOT-STUDY OF THE NATIONAL BIOTHERAPY STUDY-GROUP, Cancer biotherapy, 10(4), 1995, pp. 265-271
Authors:
DILLMAN RO
Citation: Ro. Dillman, WHITHER MAGIC BULLETS AND GUIDED MISSILES - MONOCLONAL-ANTIBODIES 20 YEARS LATER, Cancer biotherapy, 10(3), 1995, pp. 177-180
Authors:
AVENT RA
DILLMAN RO
Citation: Ra. Avent et Ro. Dillman, CANCER CLINICAL-TRIALS IN THE COMMUNITY SETTING - A 20-YEAR RETROSPECTIVE, Cancer biotherapy, 10(2), 1995, pp. 95-113
Authors:
DILLMAN RO
BARTH NM
MAHDAVI K
VANDERMOLEN LA
NAYAK SK
OCONNOR A
Citation: Ro. Dillman et al., THE INTEGRATION OF HIGH-DOSE CHEMOTHERAPY AND BIOTHERAPY - INITIAL 5-YEAR EXPERIENCE WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION IN A COMPREHENSIVE COMMUNITY CANCER CENTER, Cancer biotherapy, 10(1), 1995, pp. 25-36
Authors:
ALBERTI W
ANDERSON G
BARTOLUCCI A
BELL D
VILLALBA JB
BRODIN O
CARDIELLO C
CARTEI F
CARTEI G
CELLERINO R
CHASTANG C
CORMIER Y
COX JD
CRINO L
CROWLEY J
DAUTZENBERG B
DEPIERRE A
DIETEMANN A
DILLMAN RO
DOI O
FELD R
FIGLIN R
GANZ PA
GREEN MR
GREGOR A
HELLE PA
HERNDON JE
HITOMI S
HOST H
IMAIZUMI M
JETT JR
JOHNSON D
KAASA S
KIMURA H
KLASTERSKY J
KONDO H
KREISMAN H
KRIS MG
KUNISHIMA K
KUWAHARA O
LAD TE
LAING AH
MACBETH F
MASAOKA A
MATTSON K
MINATEL E
MIRA JG
MORI T
MOUNTAIN CF
NIEDERLE N
NIIRANEN A
NOU E
PAGE W
PATER J
PIANTADOSI S
PISTERS KMW
PYRHONEN S
QUOIX E
RAPP E
ROWELL NP
SAHMOUD T
SAWAMURA K
SCHALLIER DCC
SCOTT C
SIMPSON J
STAGG M
TERAMATSU T
TROVO MG
TSUCHIYA R
TUMMARELLO D
VANHOUTTE P
VANZANDWIJK N
VINCENT RG
WADA H
WHITE JE
WILLIAMS CJ
WOODS RL
YAMAGUCHI Y
ARRIAGADA R
CARTMELLDAVIES J
GIRLING DJ
LECHEVALIER T
MARSONI S
PARMAR MKB
PIGNON JP
REKACEWICZ C
SOUHAMI RL
STEWART LA
TARAYRE M
TINAZZI A
TONI V
Citation: W. Alberti et al., CHEMOTHERAPY IN NON-SMALL-CELL LUNG-CANCER - A METAANALYSIS USING UPDATED DATA ON INDIVIDUAL PATIENTS FROM 52 RANDOMIZED CLINICAL-TRIALS, BMJ. British medical journal, 311(7010), 1995, pp. 899-909
Authors:
KOZIOL JA
LEE PP
DILLMAN RO
FAGNANI R
HALPERN SE
Citation: Ja. Koziol et al., PHARMACOKINETICS OF IN-111-LABELED MONOCLONAL-ANTIBODY ZCE-025 AND FRAGMENTS IN TUMOR-BEARING MICE, Nuclear medicine communications, 16(4), 1995, pp. 299-305
Authors:
BEUTEL LD
NAYAK SK
DILLMAN RO
Citation: Ld. Beutel et al., USE OF AUTOLOGOUS ACTIVATED LYMPHOCYTES (AAL) FOR ADOPTIVE IMMUNOTHERAPY OF CANCER, Transfusion, 35(10), 1995, pp. 6-6